View Item 

Show simple item record

Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity
dc.contributor.authorHertz, Daniel L.
dc.contributor.authorDeal, Allison
dc.contributor.authorIbrahim, Joseph G.
dc.contributor.authorWalko, Christine M.
dc.contributor.authorWeck, Karen E.
dc.contributor.authorAnderson, Steven
dc.contributor.authorMagrinat, Gustav
dc.contributor.authorOlajide, Oludamilola
dc.contributor.authorMoore, Susan
dc.contributor.authorRaab, Rachel
dc.contributor.authorCarrizosa, Daniel R.
dc.contributor.authorCorso, Steven
dc.contributor.authorSchwartz, Garry
dc.contributor.authorGraham, Mark
dc.contributor.authorPeppercorn, Jeffrey M.
dc.contributor.authorJones, David R.
dc.contributor.authorDesta, Zeruesenay
dc.contributor.authorFlockhart, David A.
dc.contributor.authorEvans, James P.
dc.contributor.authorMcLeod, Howard L.
dc.contributor.authorCarey, Lisa A.
dc.contributor.authorIrvin, William J.
dc.date.accessioned2017-12-15T16:47:17Z
dc.date.available2017-12-15T16:47:17Z
dc.date.issued2016-07
dc.identifier.citationHertz, Daniel L.; Deal, Allison; Ibrahim, Joseph G.; Walko, Christine M.; Weck, Karen E.; Anderson, Steven; Magrinat, Gustav; Olajide, Oludamilola; Moore, Susan; Raab, Rachel; Carrizosa, Daniel R.; Corso, Steven; Schwartz, Garry; Graham, Mark; Peppercorn, Jeffrey M.; Jones, David R.; Desta, Zeruesenay; Flockhart, David A.; Evans, James P.; McLeod, Howard L.; Carey, Lisa A.; Irvin, William J. (2016). "Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity." The Oncologist 21(7): 795-803.
dc.identifier.issn1083-7159
dc.identifier.issn1549-490X
dc.identifier.urihttps://hdl.handle.net/2027.42/139937
dc.publisherAlphaMed Press
dc.publisherWiley Periodicals, Inc.
dc.subject.otherTamoxifen
dc.subject.otherCYP2D6
dc.subject.otherGenotype
dc.subject.otherRace
dc.subject.otherQuality of life
dc.subject.otherPharmacogenetics
dc.subject.otherToxicity
dc.subject.otherEndoxifen
dc.titleTamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumUniversity of Michigan, Ann Arbor, Michigan, USA
dc.contributor.affiliationotherPalmetto Hematology Oncology, Spartanburg, South Carolina, USA
dc.contributor.affiliationotherUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
dc.contributor.affiliationotherMoffitt Cancer Center, Tampa, Florida, USA
dc.contributor.affiliationotherLaboratory Corporation of America, Burlington, North Carolina, USA
dc.contributor.affiliationotherMoses Cone Health Cancer Center, Greensboro, North Carolina, USA
dc.contributor.affiliationotherREX Hematology Oncology Associates, Raleigh, North Carolina, USA
dc.contributor.affiliationotherBrody School of Medicine at East Carolina University, Greenville, North Carolina, USA
dc.contributor.affiliationotherLevine Cancer Institute, Charlotte, North Carolina, USA
dc.contributor.affiliationotherLevine Cancer Institute Concord, Concord, North Carolina, USA
dc.contributor.affiliationotherWaverly Hematology/Oncology, Cary, North Carolina, USA
dc.contributor.affiliationotherDuke University, Durham, North Carolina, USA
dc.contributor.affiliationotherIndiana University, Indianapolis, Indiana, USA
dc.contributor.affiliationotherBon Secours Cancer Institute, Richmond, Virginia, USA
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139937/1/onco0795-sup-0002.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139937/2/onco0795-sup-0001.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139937/3/onco0795.pdf
dc.identifier.doi10.1634/theoncologist.2015-0480
dc.identifier.sourceThe Oncologist
dc.identifier.citedreferenceRG Gray, D Rea, K Handley. aTTom: Long‐term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013; 31 suppl: 5a.
dc.identifier.citedreferenceC Davies, H Pan, J Godwin. Long‐term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor‐positive breast cancer: ATLAS, a randomised trial. Lancet. 2013; 381: 805 – 816.
dc.identifier.citedreferenceWA Teft, IY Gong, B Dingle. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Res Treat. 2013; 139: 95 – 105.
dc.identifier.citedreferenceLB Rangel, JL Taraba, CR Frei. Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non‐Hispanic whites with breast cancer. Breast Cancer Res Treat. 2014; 148: 571 – 580.
dc.identifier.citedreferenceNA Limdi, TM Brown, Q Yan. Race influences warfarin dose changes associated with genetic factors. Blood. 2015; 126: 539 – 545.
dc.identifier.citedreferenceSE Kimmel, B French, SE Kasner. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013; 369: 2283 – 2293.
dc.identifier.citedreferenceNL Henry, F Azzouz, Z Desta. Predictors of aromatase inhibitor discontinuation as a result of treatment‐emergent symptoms in early‐stage breast cancer. J Clin Oncol. 2012; 30: 936 – 942.
dc.identifier.citedreferenceDL Hertz, AC Snavely, JP Evans. Does increasing the daily tamoxifen dose in patients with diminished CYP2D6 activity increase toxicity?. J Clin Oncol. 2014; 32 suppl: 561a.
dc.identifier.citedreferenceI Sestak, R Kealy, M Nikoloff. Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: Results from the IBIS‐I trial. Br J Cancer. 2012; 107: 230 – 233.
dc.identifier.citedreferenceV Dezentje, H Gelderblom, RN Schaik. CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. Breast Cancer Res Treat. 2014; 143: 171 – 179.
dc.identifier.citedreferenceMP Goetz, JM Rae, VJ Suman. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005; 23: 9312 – 9318.
dc.identifier.citedreferenceNL Henry, JM Rae, L Li. Association between CYP2D6 genotype and tamoxifen‐induced hot flashes in a prospective cohort. Breast Cancer Res Treat. 2009; 117: 571 – 575.
dc.identifier.citedreferenceW Lorizio, AH Wu, MS Beattie. Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat. 2012; 132: 1107 – 1118.
dc.identifier.citedreferenceC Davies, J Godwin, R Gray. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient‐level meta‐analysis of randomised trials. Lancet. 2011; 378: 771 – 784.
dc.identifier.citedreferenceMF Barginear, M Jaremko, I Peter. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: Effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther. 2011; 90: 605 – 611.
dc.identifier.citedreferenceEarly Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1998; 351: 1451 – 1467.
dc.identifier.citedreferenceJM Rae, MJ Sikora, NL Henry. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J. 2009; 9: 258 – 264.
dc.identifier.citedreferenceK Kiyotani, T Mushiroda, CK Imamura. Dose‐adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Res Treat. 2012; 131: 137 – 145.
dc.identifier.citedreferenceLJ Fallowfield, SK Leaity, A Howell. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: Validation of an endocrine symptom subscale for the FACT‐B. Breast Cancer Res Treat. 1999; 55: 189 – 199.
dc.identifier.citedreferenceAL Stanton, CA Bernaards, PA Ganz. The BCPT symptom scales: A measure of physical symptoms for women diagnosed with or at risk for breast cancer. J Natl Cancer Inst. 2005; 97: 448 – 456.
dc.identifier.citedreferenceWJ Irvin Jr, CM Walko, KE Weck. Genotype‐guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: A multicenter study. J Clin Oncol. 2011; 29: 3232 – 3239.
dc.identifier.citedreferenceMM Regan, B Leyland‐Jones, M Bouzyk. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine‐responsive breast cancer: The Breast International Group 1‐98 trial. J Natl Cancer Inst. 2012; 104: 441 – 451.
dc.identifier.citedreferenceRae JM, Drury S, Hayes DF et al. Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial. 33rd Annual San Antonio Breast Cancer Symposium; December 8–10, 2010; San Antonio, TX.; 2010
dc.identifier.citedreferenceW Schroth, MP Goetz, U Hamann. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009; 302: 1429 – 1436.
dc.identifier.citedreferenceMP Goetz, VJ Suman, TL Hoskin. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res. 2013; 19: 500 – 507.
dc.identifier.citedreferenceAH De Vries Schultink, W Zwart, SC Linn. Effects of pharmacogenetics on the pharmacokinetics and pharmacodynamics of tamoxifen. Clin Pharmacokinet. 2015; 54: 797 – 810.
dc.identifier.citedreferenceDL Hertz, AC Snavely, HL McLeod. In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. Br J Clin Pharmacol. 2015; 80: 1122 – 1130.
dc.identifier.citedreferenceKR Crews, A Gaedigk, HM Dunnenberger. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther. 2012; 91: 321 – 326.
dc.identifier.citedreferenceTE Mürdter, W Schroth, L Bacchus‐Gerybadze. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther. 2011; 89: 708 – 717.
dc.identifier.citedreferenceRR Love, Z Desta, D Flockhart. CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer. SpringerPlus. 2013; 2: 52.
dc.identifier.citedreferenceL Madlensky, L Natarajan, S Tchu. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011; 89: 718 – 725.
dc.identifier.citedreferenceP Saladores, T Murdter, D Eccles. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J. 2014; 15: 84 – 94.
dc.identifier.citedreferenceYC Lim, Z Desta, DA Flockhart. Endoxifen (4‐hydroxy‐N‐desmethyl‐tamoxifen) has anti‐estrogenic effects in breast cancer cells with potency similar to 4‐hydroxy‐tamoxifen. Cancer Chemother Pharmacol. 2005; 55: 471 – 478.
dc.identifier.citedreferenceV Stearns, MD Johnson, JM Rae. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003; 95: 1758 – 1764.
dc.identifier.citedreferenceS Li, D Shen, J Shao. Endocrine‐therapy‐resistant ESR1 variants revealed by genomic characterization of breast‐cancer‐derived xenografts. Cell Reports. 2013; 4: 1116 – 1130.
dc.identifier.citedreferenceDR Robinson, YM Wu, P Vats. Activating ESR1 mutations in hormone‐resistant metastatic breast cancer. Nat Genet. 2013; 45: 1446 – 1451.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
onco0795-sup-0002.pdf
Size:
170.0KB
Format:
PDF
View/Open
Name:
onco0795-sup-0001.pdf
Size:
135.8KB
Format:
PDF
View/Open
Name:
onco0795.pdf
Size:
792.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.